ArticleGynecologic oncology reports2026
Government funding for uterine cancer research lags behind rising incidence.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The second largest government funding source for cancer research is the Department of Defense (DOD). The Peer Reviewed Cancer Research Program (PRCRP) is the funding mechanism for uterine cancer under the DOD. Our objective was to compile cancer research funding granted through the PRCRP by organ site and stratify by incidence of disease to highlight uterine cancer funding. Methods: To gather funding information from the PRCRP, a thorough review was done of the CDMRP website, where records of grants funded and the total budgets for the PRCRP had to be manually abstracted from archives. Results: Uterine cancer has the second highest incidence of these areas (29.4 per 100,000 in 2021), after colorectal cancer (CRC) (37.5 per 100,000 in 2021). CRC has been funded the longest at 15 years. Mesothelioma, for comparison, has the lowest incidence (0.7 per 100,000 in 2021) and has been funded for 14 years. CRC, with the highest incidence and the longest funded area, has received a total of ∼$60 million through the PRCRP. Mesothelioma, with the lowest incidence and the second longest funded area has received ∼$25 million. Uterine cancer, with the second highest incidence, and one of the shortest funded areas, has received only ∼$14 million. Additionally, the incidence of uterine cancer is rising and has seen a 14.8% increase in incidence from 2009 to 2021 whereas CRC has seen a 15.0% decrease. Conclusions: This analysis highlights a proportionate inequity in government funding for uterine cancer when considering the rising incidence of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.